Videos

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.

The discussion highlights the role of multidisciplinary collaboration in CAR-T patient care, emphasizing effective coordination among specialists, primary care providers, and community oncologists, and strategies for ensuring consistent communication and continuity of care for patients in remote locations.

The discussion delves into long-term monitoring strategies for CAR-T patients, exploring differences between academic and community settings and emerging long-term adverse effects as clinical experience with CAR-T therapy grows.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific therapy, as well as best practices for transitioning care back to the community center after therapy administration.

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for effectively initiating these discussions with patients.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Key opinion leaders compare osimertinib's adverse event profile to other EGFR inhibitors, highlighting specific challenges and benefits observed in clinical practice

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

Key opinion leaders highlight effective multidisciplinary strategies for managing the diverse range of side effects associated with EGFR inhibitors.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

This video segment examines protocols for long-term monitoring of CAR-T therapy patients, differences between academic and community settings, emerging adverse events, and strategies for multidisciplinary collaboration and care coordination to ensure seamless communication and continuity of care.

This video segment profiles a 72-year-old retired science teacher with multiple myeloma, detailing his treatment journey from VRd induction and ASCT to relapse, management of comorbidities, and receiving cilta-cel, supported by his active and healthy wife.

This segment highlights the treatment journey of a 68-year-old IT professional with high-risk multiple myeloma, detailing progression after initial D-RVd therapy, refusal of ASCT, and successful transition to cilta-cel CAR-T therapy with manageable adverse events.

The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on preventive measures and comparisons with GI management strategies for other EGFR inhibitors.

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, discussing unique challenges and benefits observed in clinical practice.

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, highlighting multidisciplinary management strategies and integrating best practices into electronic medical records.

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

The discussion focuses on monitoring and managing neurologic toxicities like ICANS in CAR-T therapy, highlighting tools for early detection, effective management strategies, and approaches to communicating risks with patients and caregivers.

Expert panelists explore approaches to grading and managing Cytokine Release Syndrome (CRS) in CAR-T therapy, discussing effective strategies to mitigate severity and key differences in CRS management protocols between ide-cel and cilta-cel.

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle support, balancing work during and after treatment, and effective supportive care measures.

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to communicating risks with patients and caregivers.

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments significantly impacted patient outcomes.

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the unique considerations of talquetamab targeting GPRC5D.